FDA approves oral urticaria drug

The U.S. Food and Drug Administration has approved oral remibrutinib for the treatment of chronic spontaneous urticaria in adult patients unresponsive to antihistamines.

The approval comes after positive findings from the phase III REMIX-1 and REMIX-2 trials, which demonstrated improvements in the Itch Severity Score, Hives Severity Score and Urticaria Activity Score over placebo after a period of 12 weeks, according to a news report from Pharmacy Times. Remibrutinib works by blocking Bruton’s tyrosine kinase activation to prevent a pro-inflammatory response following exposure to allergens.

Read more: Pharmacy Times

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.